Inhibidors del cotransportador sodi-glucosa tipus 2 (ISGLT2) i ISGLT2/metformina per al tractament de la diabetis mellitus tipus 2
Abstract
The term Diabetes Mellitus (DM) defines a series of metabolic disorders characterized by chronic hyperglycemia and disorders in the metabolism of carbohydrates, fats and proteins, as a result of defects in the secretion of insulin, action of this or in a mixture of both mechanisms. Acute manifestations, which can motivate the diagnosis, are those known as cardinal symptoms of DM (polyuria, polydipathy, polyphagia, blurred vision, and, less frequently, weight loss) and diabetic ketoacidosis (CAD, more frequent in DM type 1). In the long term, there may be microvascular complications (retinopathy, nephropathy and neuropathy) and macrovascular disorders (coronary artery disease, cerebrovascular disease and peripheral arterial disease)
Keywords
Diabetes mellitus type 2; Inhibitors of the sodium-glucose transporter; Treatment
Bibliographic citation
Programa d'harmonització farmacoterapèutica. Inhibidors del cotransportador sodi-glucosa tipus 2 (ISGLT2) i ISGLT2/metformina per al tractament de la diabetis mellitus tipus 2. Barcelona: Servei Català de la Salut; 2021.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4141This item appears in following collections
The following license files are associated with this item: